QUALITY ASSESSMENT OF CORRECTION THYROID STATUS AND LIPID PROFILE IN PATIENTS WITH HYPOTHYROIDISM

BACKGROUND Thyroid hormone is known to regulate metabolisms which are an integral part of normal growth and development. It affects key metabolisms involved in energy storage and expenditure. We wanted to study the correlation of thyroid function test with metabolic markers. METHODS After appropriate clearance from Human Institutional Ethics Committee and proper permission from author of article by Dr Sindhu et al, the secondary, blinded data was adopted for this study. This is an observational, cross-sectional retrospective study. Anthropometric measurements were taken, and lipid and thyroid profile were analysed in overnight fasting sample. As per our inclusion and exclusion criteria 120 of 253 subjects included in primary study were recruited in our study. Statistical analysis was done in Microsoft Excel 2007 and SPSS software version 16.0. ATP III criteria were used as a benchmark for metabolic syndrome markers. RESULTS Our study suggests that prevalence of subclinical hypothyroidism was higher in young South Indian women and it significantly correlated with the markers of metabolic syndrome like BMI, waist circumference, Low Density Lipoprotein (LDL) and systolic blood pressure. TSH values strongly correlated with BMI and LDL values. FT4 values correlated well with LDL. CONCLUSIONS High TSH and lower thyroxine values in blood can be a marker associated with metabolic syndrome. Our study suggests routine screening for thyroid status and lipid profile in young females to categorize them as high risk for cardiovascular mortality and morbidity along with anthropometric measurements. The study can be continued by long term follow up of the study subjects and correlation of these study subjects into mid or old age can give significant information of their cardiac status at that age. Counseling on appropriate diet and lifestyle modification may be beneficial for young people categorized as high risk to reduce the cardiovascular mortality later in life. KEYWORDS Thyroid Stimulating Hormone, Free Thyroxine, BMI, Lipid Profile

Download Full-text

Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling

BMC Medicine ◽

10.1186/s12916-021-02130-1 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Nicolien A. van Vliet ◽

Maxime M. Bos ◽

Carisha S. Thesing ◽

Layal Chaker ◽

Maik Pietzner ◽

...

Keyword(s):

Cardiovascular Disease ◽

Lipid Profile ◽

Metabolic Profile ◽

Mendelian Randomization ◽

Disease Risk ◽

Cardiovascular Disease Risk ◽

Density Lipoprotein ◽

European Ancestry ◽

Thyroid Status ◽

Genetically Determined

Abstract Background Observational studies suggest interconnections between thyroid status, metabolism, and risk of coronary artery disease (CAD), but causality remains to be proven. The present study aimed to investigate the potential causal relationship between thyroid status and cardiovascular disease and to characterize the metabolomic profile associated with thyroid status. Methods Multi-cohort two-sample Mendelian randomization (MR) was performed utilizing genome-wide significant variants as instruments for standardized thyrotropin (TSH) and free thyroxine (fT4) within the reference range. Associations between TSH and fT4 and metabolic profile were investigated in a two-stage manner: associations between TSH and fT4 and the full panel of 161 metabolomic markers were first assessed hypothesis-free, then directional consistency was assessed through Mendelian randomization, another metabolic profile platform, and in individuals with biochemically defined thyroid dysfunction. Results Circulating TSH was associated with 52/161 metabolomic markers, and fT4 levels were associated with 21/161 metabolomic markers among 9432 euthyroid individuals (median age varied from 23.0 to 75.4 years, 54.5% women). Positive associations between circulating TSH levels and concentrations of very low-density lipoprotein subclasses and components, triglycerides, and triglyceride content of lipoproteins were directionally consistent across the multivariable regression, MR, metabolomic platforms, and for individuals with hypo- and hyperthyroidism. Associations with fT4 levels inversely reflected those observed with TSH. Among 91,810 CAD cases and 656,091 controls of European ancestry, per 1-SD increase of genetically determined TSH concentration risk of CAD increased slightly, but not significantly, with an OR of 1.03 (95% CI 0.99–1.07; p value 0.16), whereas higher genetically determined fT4 levels were not associated with CAD risk (OR 1.00 per SD increase of fT4; 95% CI 0.96–1.04; p value 0.59). Conclusions Lower thyroid status leads to an unfavorable lipid profile and a somewhat increased cardiovascular disease risk.

Download Full-text

EFFICIENCY OF THE LOW-DOSE FORMS ESTROGEN-GESTAGEN DRUG TREATMENTTO WOMEN WITH COMPENSATED HYPOTHERIOSIS AND EUTHYROIDISM

HERALD of North-Western State Medical University named after I I Mechnikov ◽

10.17816/mechnikov20157140-45 ◽

2015 ◽

Vol 7 (1) ◽

pp. 40-45

Author(s):

V A Gromova ◽

N V Vorokhobina ◽

O F Malygina ◽

A V Kuznetsova

Keyword(s):

Hormone Replacement Therapy ◽

Lipid Profile ◽

Replacement Therapy ◽

Autoimmune Thyroiditis ◽

Thyroid Disease ◽

Low Dose ◽

Hormone Replacement ◽

Thyroid Status ◽

Nontoxic Goiter ◽

Progestin Therapy

The article presents research results of 61 perimenopausal and postmenopausal women with diffuse nodular nontoxic goiter and autoimmune thyroiditis, who in the 12 months received treatment low-dose combined estrogen-progestin drug, which includes a 1 mg 17-β estradiol and 2 mg drospirenone. The effect of hormone replacement therapy on coagulation and platelet hemostasis, lipid profile, pituitary-ovarian system, thyroid status were studied. Using of low-dose estrogen-progestin therapy does not worsen diffuse nodular nontoxic goiter and autoimmune thyroiditis flow, does not change the dose of thyroid medications and may be recommended for the treatment of menopausal symptoms in women with thyroid disease.

Download Full-text